[ALDX] Aldeyra Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 4.85 Change: 0.15 (3.19%)
Ext. hours: Change: 0 (0%)

chart ALDX

Refresh chart

Strongest Trends Summary For ALDX

ALDX is in the long-term up 60% above S&P in 2 years and up 62% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Aldeyra Therapeutics, Inc. develops drug candidates for capturing and removing free aldehydes to treat and prevent diseases, and slow the progression of chronic disease. The company?s products target immune-mediated, inflammatory, orphan, and other diseases. It develops NS2, a compound that binds and traps free aldehydes. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS-1.91 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-2.25
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-48.5% ROE-55.88% ROI
Current Ratio15.35 Quick Ratio Long Term Debt/Equity0.07 Debt Ratio0.07
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities9.04 M Cash From Investing Activities Cash From Operating Activities-1.84 M Gross Profit
Net Profit-2.14 M Operating Profit-2.11 M Total Assets15.93 M Total Current Assets15.9 M
Total Current Liabilities1.04 M Total Debt1.26 M Total Liabilities2.1 M Total Revenue
Technical Data
High 52 week14.35 Low 52 week6.35 Last close8.97 Last change-3.55%
RSI62.34 Average true range0.6 Beta0.71 Volume13.12 K
Simple moving average 20 days3.11% Simple moving average 50 days-2.4% Simple moving average 200 days2.04%
Performance Data
Performance Week-7.62% Performance Month-5.18% Performance Quart-27.66% Performance Half11.43%
Performance Year32.89% Performance Year-to-date8.07% Volatility daily4.44% Volatility weekly9.94%
Volatility monthly20.37% Volatility yearly70.56% Relative Volume214.91% Average Volume214.62 K
New High New Low

News

2019-03-13 10:35:02 | Options Traders Expect Huge Moves in Aldeyra ALDX Stock

2019-03-08 12:12:00 | Aldeyra Therapeutics Inc ALDX Q4 2018 Earnings Conference Call Transcript

2019-03-08 12:04:13 | Edited Transcript of ALDX earnings conference call or presentation 8-Mar-19 1:00pm GMT

2019-03-08 07:00:00 | Aldeyra Therapeutics Announces Year-End 2018 Financial Results

2019-03-01 08:00:00 | Aldeyra Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results and Host Conference Call on Friday, March 8, 2019

2019-02-28 07:00:00 | Aldeyra Therapeutics Provides Update on Ophthalmic Programs at 2019 Research & Development Day

2019-02-12 08:00:00 | Aldeyra Therapeutics to Host 2019 Research & Development Day

2019-01-30 07:55:00 | Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2019-01-29 08:00:00 | Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision

2019-01-15 08:00:00 | Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations

2019-01-03 08:00:00 | Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer

2018-12-20 08:00:00 | Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial

2018-12-17 21:42:35 | Should You Buy Aldeyra Therapeutics Inc ALDX?

2018-11-30 12:48:21 | Should You Be Concerned About Aldeyra Therapeutics Inc’s NASDAQ:ALDX Historical Volatility?

2018-11-28 08:00:00 | Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference

2018-11-14 11:27:05 | Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT

2018-11-14 07:00:00 | Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results

2018-11-08 08:35:00 | Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-06 08:00:00 | Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference

2018-11-05 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results

2018-10-16 14:46:39 | Research Report Identifies Aldeyra Therapeutics, AAON, Douglas Dynamics, Insmed, Northern Oil and Gas, and SMART Global with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

2018-10-02 09:32:59 | Mangrove Partners: Performance, AUM, and Holdings

2018-09-28 10:06:02 | Aldeyra Therapeutics ALDX Looks Good: Stock Adds 7.5% in Session

2018-09-28 08:00:00 | Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

2018-09-27 20:00:00 | Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock

2018-09-27 09:12:01 | Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap

2018-09-27 08:20:53 | The Daily Biotech Pulse: Hologic Goes Shopping, Johnson & Johnson Snaps Ties With Geron

2018-09-27 08:00:00 | Today’s Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals

2018-09-26 16:01:00 | Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

2018-09-26 12:54:31 | Aldeyra Therapeutics Stock Skyrockets on Dry Eye Study Results

2018-09-26 08:25:04 | The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial

2018-09-26 08:12:00 | Alderya's stock rockets after positive trial results of mesothelioma treatment

2018-09-26 07:00:00 | Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial

2018-09-25 16:30:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial

2018-09-25 08:00:00 | Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer

2018-09-06 08:52:12 | Implied Volatility Surging for Aldeyra Therapeutics ALDX Stock Options

2018-08-17 08:20:00 | Consolidated Research: 2018 Summary Expectations for PDF Solutions, MYOS RENS Technology, Aldeyra Therapeutics, The Ensign Group, Everi, and Ardelyx — Fundamental Analysis, Key Performance Indications

2018-08-09 07:30:00 | Aldeyra Therapeutics Announces Second Quarter 2018 Financial Results and Provides Corporate Update

2018-08-09 06:00:00 | Aldeyra Therapeutics, Inc. to Host Earnings Call

2018-08-02 08:00:00 | Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Second Quarter 2018 Financial Results and Corporate Update

2018-08-01 08:00:00 | Aldeyra Therapeutics to Present at the 38th Annual Canaccord Genuity Growth Conference

2018-07-31 08:00:00 | Aldeyra Therapeutics Appoints Joshua Reed as Chief Financial Officer

2018-07-24 08:00:00 | Aldeyra Therapeutics Announces First Patient Enrolled in Sjögren-Larsson Syndrome Pivotal Phase 3 Clinical Trial

2018-07-23 15:42:16 | Why Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today

2018-07-12 08:00:00 | Aldeyra Therapeutics Announces Last Patient Dosed in Dry Eye Disease Phase 2b Clinical Trial

2018-06-26 08:00:00 | Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

2018-06-25 16:01:00 | Aldeyra Therapeutics Joins the Russell 3000® and 2000® Indexes

2018-06-20 08:00:00 | Aldeyra Therapeutics Announces 2018 Research Day

2018-05-30 07:45:00 | Analysis: Positioning to Benefit within Aldeyra Therapeutics, Freightcar America, Bank of Hawaii, Heritage-Crystal Clean, Amedisys, and U.S. Global Investors — Research Highlights Growth, Revenue, and Consolidated Results

2018-05-15 07:30:00 | Aldeyra Therapeutics Announces First Quarter 2018 Financial Results